Featured Research

from universities, journals, and other organizations

Michigan Team Singles Out Cancer Stem Cells For Attack

Date:
May 6, 2006
Source:
University Of Michigan Life Sciences Institute
Summary:
Close on the heels of the discovery that cancer has its own rejuvenating stem cells, a University of Michigan research team has found a way to distinguish these bad-actors from the normal stem cells that they so closely resemble, and to kill the cancer stem cells without harming the normal stem cells in the same tissue.

A cluster of leukemia-forming cells from a mouse lacking the Pten gene. Blood-forming stem cells and leukemia-initiating cells differ in their dependence on Pten, and this difference can be used to selectively kill the cancerous cells without harming normal stem cells.
Credit: Photo by Omer Yilmaz, U-M Center for Stem Cell Biology

Close on the heels of the discovery that cancer has its own rejuvenating stem cells, a University of Michigan research team has found a way to distinguish these bad-actors from the normal stem cells that they so closely resemble, and to kill the cancer stem cells without harming the normal stem cells in the same tissue.

The progression of some cancers, including leukemia, appears to be driven by cancer stem cells - rare cancer cells that have a greater ability to proliferate than other cancer cells and which are therefore the most malignant. To have any hope of curing cancer it is necessary to develop therapies that kill these cancer stem cells. Yet these cells frequently have properties that are similar to normal stem cells in the same tissue, making it difficult to kill cancer stem cells without damaging the normal stem cells.

"This study proves that it is possible to identify differences in the mechanisms that maintain normal stem cells and cancer stem cells, and to therapeutically exploit these differences to kill the cancer stem cells without harming normal stem cells in the same tissue," said Sean J. Morrison PhD, lead author on the study and the Director of U-M's Center for Stem Cell Biology, LSI research associate professor and associate professor of internal medicine in the Medical School. Morrison is also a Howard Hughes Medical Institute investigator.

Three years ago, Morrison was part of a U-M team that made the breakthrough discovery that breast cancer has its own stem cells. These cells appear to be the primary drivers in tumor growth and possibly metastasis and the discovery pointed to a new direction in cancer therapy: Rather than trying to eliminate every last tumor cell, cancer therapies might be more specifically targeted at just the stem cells in cancer.

But telling the bad guys from the good guys - normal adult stem cells that the body relies on to replace cells damaged by injury, disease and old age - is a big problem, because they have so many features in common, Morrison explained.

In a new paper appearing as the advance online publication in Nature for April 5, 2006 (to be published in print in the near future), Morrison's team has found a way to tell stem cell friends from foes, as well as a drug that can make them behave differently.

"In many types of tumors, the gene Pten is missing or turned off," Morrison said. "Because Pten regulates cell proliferation and survival, we studied its role in the maintenance of normal blood-forming stem cells."

Omer Yilmaz, a graduate student in the Morrison laboratory, deleted the Pten gene from adult blood-forming stem cells in mice and found that the loss of Pten led to leukemia, marked by the generation of leukemic stem cells. Transplantation of even a single leukemic stem cell from these Pten -deficient mice into a second mouse caused leukemia, demonstrating the powerful cancer-causing ability of these cells.

In addition to pumping up leukemic stem cell numbers, Pten deletion also caused normal blood-forming stem cells to start dividing, but over time the normal stem cells became depleted in the absence of Pten. Additional experiments by the team established that every blood-forming stem cell needs Pten to maintain itself, in contrast to leukemic stem cells that thrive without Pten.

This finding of a key difference between normal stem cells and cancer stem cells suggested that drugs that target the metabolic pathway in which Pten acts should have opposite effects on normal blood-forming stem cells and leukemic stem cells. To test this, the team treated the mice with rapamycin, a drug that reduces the activity of this metabolic pathway. The drug is used to prevent tissue rejection in transplant patients, and is currently being tested in clinical trials for activity against a variety of cancers.

They found that rapamycin inhibited the creation and maintenance of leukemic stem cells. And even better, it "rescued" the function of normal blood-forming stem cells in these mice, that otherwise crashed without Pten.

Mice that were put on rapamycin immediately after Pten deletion failed to develop leukemia. Mice that already had leukemia were kept alive longer by the drug.

These results suggest that by better understanding the mechanisms that regulate the maintenance of normal stem cells it will be possible to develop new anti-cancer therapies that are more effective and less toxic. This is particularly important issue for leukemia patients that often cannot be cured with current therapies, and for whom existing therapies sometimes have fatal side-effects.

"The ability to strategically target and kill leukemia-initiating stem cells will undoubtedly have a significant impact on our capacity to treat these often fatal diseases more effectively," said Riccardo Valdez, M.D. an assistant professor of pathology at U-M who participated in the study. "At the same time, it would minimize potentially life-threatening side effects caused by conventional drugs."

Morrison is quick to point out that these findings are limited to mice so far, and cannot be immediately extrapolated to human patients. However, the study raises the possibility that rapamycin could be effective in depleting leukemic stem cells for at least certain patients. Clinical trials will be required to test this in human patients.


Story Source:

The above story is based on materials provided by University Of Michigan Life Sciences Institute. Note: Materials may be edited for content and length.


Cite This Page:

University Of Michigan Life Sciences Institute. "Michigan Team Singles Out Cancer Stem Cells For Attack." ScienceDaily. ScienceDaily, 6 May 2006. <www.sciencedaily.com/releases/2006/05/060506234206.htm>.
University Of Michigan Life Sciences Institute. (2006, May 6). Michigan Team Singles Out Cancer Stem Cells For Attack. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2006/05/060506234206.htm
University Of Michigan Life Sciences Institute. "Michigan Team Singles Out Cancer Stem Cells For Attack." ScienceDaily. www.sciencedaily.com/releases/2006/05/060506234206.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins